Literature DB >> 16872319

Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer.

Atsushi Ishiguro1, Takenori Takahata, Masato Saito, Gen Yoshiya, Yoshihiro Tamura, Mutsuo Sasaki, Akihiro Munakata.   

Abstract

BACKGROUND AND AIM: Genetic silencing by promoter methylation has attracted attention in the carcinogenesis of colorectal cancer. Methylation of the p16(INK4a) gene has been found in primary colorectal cancer. Although the p15(INK4b) gene displays high homology to the p16(INK4a) gene in the amino acid sequence, methylation of p15(INK4b) has not been fully studied. We investigated p15(INK4b) methylation status in patients with colorectal cancer to verify the association between the methylation of p15(INK4b) and clinicopathological features compared with p16(INK4a).
METHODS: DNA samples from the tissues of primary colorectal cancer and corresponding adjacent normal colon mucosa were obtained from surgical resections of 88 patients (47 males and 41 females, aged 29-83 years). Methylation-specific polymerase chain reaction was used to analyze p15(INK4b) and p16(INK4a) methylation status after bisulfite modification. Cumulative survival rates (mean follow-up period: 53.2 months) were calculated by the Kaplan-Meier analysis. Methylations of p15(INK4b) and p16(INK4a) genes were detected in 23 (26.1%) and 20 (22.7%) colorectal cancers, respectively.
RESULTS: Methylation of p15(INK4b) was not associated with any clinicopathological features. Compared with normal mucosa, the methylation of p15(INK4b) was more prominent in tumor tissue (P < 0.001). Reverse transcription-polymerase chain reaction (RT-PCR) revealed that p15(INK4b) methylaton decreased mRNA expression. Kaplan-Meier analysis showed that patients with stage I-II had a significant difference in survival rate between those with and without methylated p15(INK4b) (P = 0.018).
CONCLUSIONS: Our results suggest that methylation of the p15(INK4b) gene contributes to the process of carcinogenesis in colorectal cancer as well as p16(INK4a) and is useful as a prognostic factor in the early stage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16872319     DOI: 10.1111/j.1440-1746.2006.04137.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  20 in total

Review 1.  Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.

Authors:  Kaori Shima; Katsuhiko Nosho; Yoshifumi Baba; Mami Cantor; Jeffrey A Meyerhardt; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

Review 2.  DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer.

Authors:  Yutaka Hashimoto; Timothy J Zumwalt; Ajay Goel
Journal:  Epigenomics       Date:  2016-04-22       Impact factor: 4.778

3.  Galectin-4 functions as a tumor suppressor of human colorectal cancer.

Authors:  Arun Satelli; Prema S Rao; Seshadri Thirumala; U Subrahmanyeswara Rao
Journal:  Int J Cancer       Date:  2010-12-09       Impact factor: 7.396

4.  Aberrant p16((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity.

Authors:  Hiroyuki Mitomi; Naoshi Fukui; Nobuho Tanaka; Hideki Kanazawa; Tsuyoshi Saito; Takashi Matsuoka; Takashi Yao
Journal:  J Cancer Res Clin Oncol       Date:  2010-02       Impact factor: 4.553

5.  Long noncoding RNA LINC01296 plays an oncogenic role in colorectal cancer by suppressing p15 expression.

Authors:  Jianing Xu; Zhehao Zhang; Dong Shen; Ting Zhang; Jinsong Zhang; Wei De
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

6.  The blues of P(16)INK(4a): aberrant promoter methylation and association with colorectal cancer in the Kashmir valley.

Authors:  A Syed Sameer; Safiya Abdullah; Saniya Nissar; Roohi Rasool; Zaffar A Shah; Dil Afroze; Nissar A Chowdri; Mushtaq A Siddiqi
Journal:  Mol Med Rep       Date:  2012-01-03       Impact factor: 2.952

Review 7.  The Prognostic Value of p16 Hypermethylation in Cancer: A Meta-Analysis.

Authors:  Xiang-Bin Xing; Wei-Bin Cai; Liang Luo; Long-Shan Liu; Hui-Juan Shi; Min-Hu Chen
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

8.  Quantitative analysis of cancer-associated gene methylation connected to risk factors in Korean colorectal cancer patients.

Authors:  Ho-Jin Kang; Eun-Jeong Kim; Byoung-Gwon Kim; Chang-Hun You; Sang-Yong Lee; Dong-Il Kim; Young-Seoub Hong
Journal:  J Prev Med Public Health       Date:  2012-07-31

Review 9.  The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis.

Authors:  X Xing; W Cai; H Shi; Y Wang; M Li; J Jiao; M Chen
Journal:  Br J Cancer       Date:  2013-05-23       Impact factor: 7.640

10.  Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.

Authors:  Terje Ahlquist; Guro E Lind; Vera L Costa; Gunn I Meling; Morten Vatn; Geir S Hoff; Torleiv O Rognum; Rolf I Skotheim; Espen Thiis-Evensen; Ragnhild A Lothe
Journal:  Mol Cancer       Date:  2008-12-31       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.